Diabetic patients who take anti-diabetic drugs—known as glitazones—long term had a lower risk of primary and secondary brain cancer compared with diabetic patients on other medications, new research has found. The study suggests these drugs could be repurposed to prevent brain metastasis in cancer patients who are at high risk of secondary cancers. PPAR- α agonists (fibrates) and PPAR γ agonists (glitazones) drugs are clinically important due to their widespread safe use to treat high cholesterol (hyperlipidemia) and diabetes. Previous studies have suggested that fibrates and glitazones may have a role in brain tumor prevention. Given the safety and cost...